A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive

Study Type	Treatment
Sponsor Name	Merck
Disease type	Non-Small Cell Lung Cancer
Disease Stage	IV
Clinical Status	First line
Phase	III
Intervention / Treatment	Pembrolizumab + Ipilimumab vs Ipilumumab + Placebo
Research Site	St. Mary’s Hospital
Investigator	Dr Adrian Langleben
Coordinator	Dora Bartulovic
Telephone number
Fax number	–
Study start date	October 5, 2017
Study end date
Trial Status	Recruiting